12:00 AM
 | 
Apr 08, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

APS001F: Phase I/II started

Anaeropharma began a dose-escalation, U.S. Phase I/II trial to evaluate IV APS001F given on days 1-3 of a 28-day cycle...

Read the full 76 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >